Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Nov 07, 2023

SELL
$16.3 - $19.41 $244 - $291
-15 Closed
0 $0
Q4 2022

Nov 07, 2023

SELL
$14.96 - $17.39 $748 - $869
-50 Reduced 76.92%
15 $241,000
Q3 2022

Nov 07, 2023

BUY
$15.68 - $22.27 $15 - $22
1 Added 1.56%
65 $1.02 Million
Q2 2022

Nov 07, 2023

BUY
$17.44 - $23.16 $348 - $463
20 Added 45.45%
64 $1.33 Million
Q1 2022

Nov 07, 2023

BUY
$17.03 - $22.67 $187 - $249
11 Added 33.33%
44 $997,000
Q4 2021

Nov 07, 2023

BUY
$15.84 - $21.88 $522 - $722
33 New
33 $603,000
Q1 2018

Nov 06, 2023

SELL
$22.15 - $31.89 $9,746 - $14,031
-440 Closed
0 $0
Q4 2017

Nov 06, 2023

BUY
$24.23 - $30.93 $10,661 - $13,609
440
440 $13.4 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Sutton Wealth Advisors Inc. Portfolio

Follow Sutton Wealth Advisors Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sutton Wealth Advisors Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sutton Wealth Advisors Inc. with notifications on news.